Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives Average Rating of “Moderate Buy” from Analysts

Corcept Therapeutics Incorporated (NASDAQ:CORT) has earned an average rating of “Moderate Buy” from the eight research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $94.6667.

A number of research firms have recently commented on CORT. Wolfe Research lowered Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price target on the stock. in a research report on Monday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Corcept Therapeutics in a research report on Wednesday, June 24th. Truist Financial raised Corcept Therapeutics to a “strong-buy” rating in a research note on Monday, June 15th. HC Wainwright raised their target price on shares of Corcept Therapeutics from $75.00 to $95.00 and gave the stock a “buy” rating in a report on Tuesday, June 2nd. Finally, Zacks Research raised shares of Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 4th.

Corcept Therapeutics News Roundup

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Quarterly results exceeded expectations. Second-quarter revenue increased 31.7% year over year to $256.1 million, ahead of the roughly $221 million consensus. Adjusted earnings were $0.36 per share, substantially above estimates ranging from a $0.04 loss to approximately $0.02 in profit, and above $0.29 a year earlier. Zacks earnings report
• Positive Sentiment: Profitability and cash generation improved. Operating profit rose 54.8% to $41.3 million, net income reached $42.1 million, and operating cash flow was $33.5 million. Corcept ended the quarter with $111 million in cash and modest capital spending, supporting investment in its pipeline and commercial operations. Quiver Quantitative earnings summary
• Positive Sentiment: Full-year revenue guidance was raised. Management now expects 2026 revenue of $1.1 billion to $1.2 billion, above the approximately $1.0 billion analyst consensus. Executives cited strong momentum in the oncology and Cushing’s syndrome businesses. Corcept second-quarter results
• Neutral Sentiment: Analyst expectations are mixed. Recent price targets range from $72 to $135, with a median of $91.50, indicating considerable disagreement about Corcept’s valuation and growth prospects.
• Negative Sentiment: Wolfe Research downgraded CORT to Underperform. The downgrade creates a near-term counterweight to the earnings beat and higher guidance. Wolfe Research downgrade
• Negative Sentiment: Insider selling remains a concern. Quiver reported 34 insider sales versus two purchases over the past six months, including sales by several executives. In addition, the stock’s very high price-to-earnings ratio leaves it vulnerable if growth or guidance disappoints.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, insider William Guyer sold 20,000 shares of Corcept Therapeutics stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $93.13, for a total value of $1,862,600.00. Following the sale, the insider owned 3,985 shares of the company’s stock, valued at $371,123.05. This trade represents a 83.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director James N. Wilson sold 10,000 shares of the business’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $83.20, for a total value of $832,000.00. Following the completion of the sale, the director owned 1,094,543 shares in the company, valued at approximately $91,065,977.60. This trade represents a 0.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 300,000 shares of company stock valued at $22,088,050 over the last quarter. 20.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Corcept Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CORT. Pathstone Holdings LLC boosted its position in Corcept Therapeutics by 0.8% during the 3rd quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock worth $1,497,000 after acquiring an additional 144 shares during the last quarter. State of Wyoming lifted its position in shares of Corcept Therapeutics by 29.5% in the first quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 186 shares in the last quarter. Gould Capital LLC boosted its holdings in Corcept Therapeutics by 50.0% during the third quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 200 shares during the last quarter. Sequoia Financial Advisors LLC grew its position in Corcept Therapeutics by 3.7% in the fourth quarter. Sequoia Financial Advisors LLC now owns 6,904 shares of the biotechnology company’s stock valued at $240,000 after purchasing an additional 247 shares in the last quarter. Finally, Evergreen Capital Management LLC grew its position in Corcept Therapeutics by 3.0% in the fourth quarter. Evergreen Capital Management LLC now owns 8,609 shares of the biotechnology company’s stock valued at $300,000 after purchasing an additional 248 shares in the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

Corcept Therapeutics Trading Down 1.3%

Shares of Corcept Therapeutics stock opened at $92.95 on Thursday. The company has a market capitalization of $9.98 billion, a PE ratio of 265.58 and a beta of 0.47. Corcept Therapeutics has a 12 month low of $28.66 and a 12 month high of $97.63. The stock’s fifty day simple moving average is $82.51 and its 200 day simple moving average is $55.80.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.34. Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.The firm had revenue of $256.15 million for the quarter, compared to analyst estimates of $221.15 million. During the same period in the previous year, the company posted $0.29 earnings per share. The company’s revenue for the quarter was up 31.7% on a year-over-year basis. Analysts predict that Corcept Therapeutics will post 0.53 EPS for the current fiscal year.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.